NR 546 Exam 1 Actual Exam V1 | NR 546 Advanced
Psychopharmacology for the PMHNP (NR546 Exam 1) [PDF] |
Chamberlain University
1. A patient is prescribed a medication that acts as a partial agonist at the Dopamine D2
receptor. Which of the following best describes the effect of this medication?
A. It activates the receptor to a sub-maximal level compared to a full agonist, potentially
acting as an antagonist in high-dopamine environments.
B. It completely blocks all dopamine activity at the receptor site regardless of
neurotransmitter concentration.
C. It induces a conformational change that produces an effect opposite to that of a full
agonist.
D. It increases the synthesis of dopamine within the presynaptic neuron to enhance signal
transmission.
Answer: A
Rationale: Partial agonists bind to the receptor but produce a lower maximum response
than full agonists. In the presence of high levels of a full agonist (like dopamine in certain
brain regions), a partial agonist acts as a functional antagonist by competing for binding
sites. This property allows for ‘dopamine tuning,’ which is clinically useful in treating
conditions like schizophrenia where dopamine activity varies across different pathways.
2. A PMHNP is considering the use of a drug that is a substrate of the CYP2D6 enzyme. The
patient is known to be a ‘Poor Metabolizer’ based on pharmacogenomic testing. What is the
most likely clinical consequence?
A. The patient will require a significantly higher dose to achieve therapeutic effect.
B. The drug will be cleared from the body much faster than average.
C. The patient is at a higher risk for toxicity and side effects at standard doses.
D. The drug will not be absorbed in the gastrointestinal tract efficiently.
Answer: C
Rationale: Poor metabolizers lack the necessary enzyme activity to break down drugs
metabolized by CYP2D6 at a normal rate. This leads to higher-than-expected plasma
concentrations of the medication even when standard doses are administered.
Consequently, these patients are at a significantly increased risk for dose-dependent
adverse effects and toxicity.
,3. Which neurotransmitter is primarily responsible for inhibitory signaling in the central
nervous system, effectively ‘braking’ neuronal activity?
A. Glutamate
B. Acetylcholine
C. Norepinephrine
D. GABA (Gamma-Aminobutyric Acid)
Answer: D
Rationale: GABA is the major inhibitory neurotransmitter in the mammalian central
nervous system. It works by opening chloride channels or G-protein coupled receptors to
hyperpolarize the neuron, making it less likely to fire an action potential. This inhibitory
action is critical for balancing the excitatory effects of glutamate and preventing neuronal
over-excitation.
4. A patient experiences ‘orthostatic hypotension’ shortly after starting an antipsychotic
medication. Blockade of which receptor type is most likely responsible for this side effect?
A. Muscarinic M1 receptors
B. Serotonin 5-HT2A receptors
C. Histamine H1 receptors
D. Alpha-1 adrenergic receptors
Answer: D
Rationale: Alpha-1 adrenergic receptor antagonism prevents norepinephrine from causing
vasoconstriction in peripheral blood vessels. When these receptors are blocked, the body
cannot compensate for changes in posture, leading to a drop in blood pressure upon
standing. This is a common side effect of several psychotropic medications, particularly
low-potency antipsychotics and certain antidepressants.
5. The ‘Mesolimbic Pathway’ is most closely associated with which of the following functions
in the brain?
A. Reward, motivation, and psychosis
B. Prolactin secretion regulation
C. Motor movement and coordination
D. Executive function and cognitive control
Answer: A
Rationale: The mesolimbic dopamine pathway projects from the ventral tegmental area
(VTA) to the nucleus accumbens. It plays a central role in the ‘reward circuit’ and is
, involved in the mediation of pleasure and motivation. Overactivity in this specific pathway
is hypothesized to contribute to the positive symptoms of schizophrenia, such as
hallucinations and delusions.
6. What is the primary mechanism by which Selective Serotonin Reuptake Inhibitors (SSRIs)
increase synaptic serotonin levels?
A. Increasing the production of Tryptophan Hydroxylase
B. Inhibiting the Serotonin Transporter (SERT)
C. Directly stimulating the release of serotonin from presynaptic vesicles
D. Blocking the Monoamine Oxidase enzyme in the synaptic cleft
Answer: B
Rationale: SSRIs work by binding to and inhibiting the Serotonin Transporter (SERT) on
the presynaptic neuron. By blocking the reuptake of serotonin back into the neuron, the
concentration of the neurotransmitter in the synaptic cleft remains elevated for a longer
period. This increased availability allows for enhanced signaling at the postsynaptic
receptors, which eventually leads to therapeutic changes in downstream gene expression.
7. A patient is taking Lithium for Bipolar Disorder. Which of the following factors would most
likely increase the risk of Lithium toxicity?
A. A high-sodium diet
B. Excessive water intake
C. Concurrent use of an NSAID like Ibuprofen
D. Switching to a high-protein diet
Answer: C
Rationale: NSAIDs can reduce renal blood flow and inhibit the renal clearance of lithium,
leading to potentially toxic accumulation. Lithium is handled by the kidneys in a manner
similar to sodium, so factors that decrease renal function or cause sodium depletion can
increase lithium levels. PMHNPs must monitor lithium levels closely whenever a patient
starts or stops a medication that affects renal clearance.
8. Which receptor blockade is primarily responsible for the weight gain and sedation
associated with many atypical antipsychotics?
A. Alpha-2 adrenergic receptors
B. D2 and D4 receptors
C. 5-HT2C and H1 receptors
D. Beta-1 adrenergic receptors
Psychopharmacology for the PMHNP (NR546 Exam 1) [PDF] |
Chamberlain University
1. A patient is prescribed a medication that acts as a partial agonist at the Dopamine D2
receptor. Which of the following best describes the effect of this medication?
A. It activates the receptor to a sub-maximal level compared to a full agonist, potentially
acting as an antagonist in high-dopamine environments.
B. It completely blocks all dopamine activity at the receptor site regardless of
neurotransmitter concentration.
C. It induces a conformational change that produces an effect opposite to that of a full
agonist.
D. It increases the synthesis of dopamine within the presynaptic neuron to enhance signal
transmission.
Answer: A
Rationale: Partial agonists bind to the receptor but produce a lower maximum response
than full agonists. In the presence of high levels of a full agonist (like dopamine in certain
brain regions), a partial agonist acts as a functional antagonist by competing for binding
sites. This property allows for ‘dopamine tuning,’ which is clinically useful in treating
conditions like schizophrenia where dopamine activity varies across different pathways.
2. A PMHNP is considering the use of a drug that is a substrate of the CYP2D6 enzyme. The
patient is known to be a ‘Poor Metabolizer’ based on pharmacogenomic testing. What is the
most likely clinical consequence?
A. The patient will require a significantly higher dose to achieve therapeutic effect.
B. The drug will be cleared from the body much faster than average.
C. The patient is at a higher risk for toxicity and side effects at standard doses.
D. The drug will not be absorbed in the gastrointestinal tract efficiently.
Answer: C
Rationale: Poor metabolizers lack the necessary enzyme activity to break down drugs
metabolized by CYP2D6 at a normal rate. This leads to higher-than-expected plasma
concentrations of the medication even when standard doses are administered.
Consequently, these patients are at a significantly increased risk for dose-dependent
adverse effects and toxicity.
,3. Which neurotransmitter is primarily responsible for inhibitory signaling in the central
nervous system, effectively ‘braking’ neuronal activity?
A. Glutamate
B. Acetylcholine
C. Norepinephrine
D. GABA (Gamma-Aminobutyric Acid)
Answer: D
Rationale: GABA is the major inhibitory neurotransmitter in the mammalian central
nervous system. It works by opening chloride channels or G-protein coupled receptors to
hyperpolarize the neuron, making it less likely to fire an action potential. This inhibitory
action is critical for balancing the excitatory effects of glutamate and preventing neuronal
over-excitation.
4. A patient experiences ‘orthostatic hypotension’ shortly after starting an antipsychotic
medication. Blockade of which receptor type is most likely responsible for this side effect?
A. Muscarinic M1 receptors
B. Serotonin 5-HT2A receptors
C. Histamine H1 receptors
D. Alpha-1 adrenergic receptors
Answer: D
Rationale: Alpha-1 adrenergic receptor antagonism prevents norepinephrine from causing
vasoconstriction in peripheral blood vessels. When these receptors are blocked, the body
cannot compensate for changes in posture, leading to a drop in blood pressure upon
standing. This is a common side effect of several psychotropic medications, particularly
low-potency antipsychotics and certain antidepressants.
5. The ‘Mesolimbic Pathway’ is most closely associated with which of the following functions
in the brain?
A. Reward, motivation, and psychosis
B. Prolactin secretion regulation
C. Motor movement and coordination
D. Executive function and cognitive control
Answer: A
Rationale: The mesolimbic dopamine pathway projects from the ventral tegmental area
(VTA) to the nucleus accumbens. It plays a central role in the ‘reward circuit’ and is
, involved in the mediation of pleasure and motivation. Overactivity in this specific pathway
is hypothesized to contribute to the positive symptoms of schizophrenia, such as
hallucinations and delusions.
6. What is the primary mechanism by which Selective Serotonin Reuptake Inhibitors (SSRIs)
increase synaptic serotonin levels?
A. Increasing the production of Tryptophan Hydroxylase
B. Inhibiting the Serotonin Transporter (SERT)
C. Directly stimulating the release of serotonin from presynaptic vesicles
D. Blocking the Monoamine Oxidase enzyme in the synaptic cleft
Answer: B
Rationale: SSRIs work by binding to and inhibiting the Serotonin Transporter (SERT) on
the presynaptic neuron. By blocking the reuptake of serotonin back into the neuron, the
concentration of the neurotransmitter in the synaptic cleft remains elevated for a longer
period. This increased availability allows for enhanced signaling at the postsynaptic
receptors, which eventually leads to therapeutic changes in downstream gene expression.
7. A patient is taking Lithium for Bipolar Disorder. Which of the following factors would most
likely increase the risk of Lithium toxicity?
A. A high-sodium diet
B. Excessive water intake
C. Concurrent use of an NSAID like Ibuprofen
D. Switching to a high-protein diet
Answer: C
Rationale: NSAIDs can reduce renal blood flow and inhibit the renal clearance of lithium,
leading to potentially toxic accumulation. Lithium is handled by the kidneys in a manner
similar to sodium, so factors that decrease renal function or cause sodium depletion can
increase lithium levels. PMHNPs must monitor lithium levels closely whenever a patient
starts or stops a medication that affects renal clearance.
8. Which receptor blockade is primarily responsible for the weight gain and sedation
associated with many atypical antipsychotics?
A. Alpha-2 adrenergic receptors
B. D2 and D4 receptors
C. 5-HT2C and H1 receptors
D. Beta-1 adrenergic receptors
